| Page 36 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications

The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also cause lifelong complications.

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

Author(s): 
Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C
Primary Author: 
Abel GA
Journal Title: 
Leukemia
Original Publication Date: 
Jan 2021
Bone Marrow Disease(s): 

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Author(s): 
Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K
Primary Author: 
Garcia-Manero G
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Jan 2021
Bone Marrow Disease(s): 

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

Author(s): 
Russell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan
Primary Author: 
Lewis R
Journal Title: 
Cancer Management and Research
Original Publication Date: 
Jan 2021

For the majority of patients with lower-risk myelodysplastic syndrome (LR-MDS), one of the primary clinical goals is to alleviate the symptoms associated with the resultant cytopenias and to minimize the transfusion burden. While supportive

Bone Marrow Disease(s): 

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

Author(s): 
Jesus D Gonzalez-Lugo, Samarpana Chakraborty, Amit Verma, Aditi Shastri
Primary Author: 
Gonzalez-Lugo J
Journal Title: 
Seminars in Hematology
Original Publication Date: 
Jan 2021

Mutations in the group of epigenetic modifiers are the largest group of mutated genes in

Bone Marrow Disease(s): 

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"

Author(s): 
Mrinal M Patnaik, Ayalew Tefferi
Primary Author: 
Patnaik M
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Jan 2021

Disease overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include

Bone Marrow Disease(s): 

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Author(s): 
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM
Primary Author: 
Sallman DA
Journal Title: 
Journal of clinical oncology: official journal of the American Society Clinical Oncology
Original Publication Date: 
Jan 2021

Purpose: Approximately 20% of patients with TP53-mutant

Bone Marrow Disease(s):